Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.
暂无分享,去创建一个
[1] B. B. Mettelman,et al. Randomized Trial of 42-Day Compared with 9-Day Courses of Dexamethasone for the Treatment of Evolving Bronchopulmonary Dysplasia in Extremely Preterm Infants. , 2019, The Journal of pediatrics.
[2] A. V. van Kaam,et al. Duration of mechanical ventilation and neurodevelopment in preterm infants , 2019, Archives of Disease in Childhood: Fetal and Neonatal Edition.
[3] F. Cools,et al. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial , 2019, JAMA.
[4] A. V. van Kaam,et al. Restricted Ventilation Associated with Reduced Neurodevelopmental Impairment in Preterm Infants , 2017, Neonatology.
[5] E. Bancalari,et al. The Evolution of Bronchopulmonary Dysplasia after 50 Years. , 2017, American journal of respiratory and critical care medicine.
[6] R. Lewis,et al. Confounding by Indication in Clinical Research. , 2016, JAMA.
[7] L. Doyle,et al. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. , 2014, The Journal of pediatrics.
[8] L. Doyle,et al. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2014, The Cochrane database of systematic reviews.
[9] Bethany J Figg,et al. National Institute of Child Health and Human Development , 2013 .
[10] Neil Marlow,et al. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies) , 2012, BMJ : British Medical Journal.
[11] A. Jefferies. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. , 2012, Paediatrics & child health.
[12] L. Doyle,et al. Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.
[13] K. Watterberg. Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia , 2010, Pediatrics.
[14] A. V. van Kaam,et al. Open-Label Glucocorticoids Modulate Dexamethasone Trial Results in Preterm Infants , 2010, Pediatrics.
[15] B. Poindexter,et al. Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network , 2010, Pediatrics.
[16] L. Doyle,et al. Postnatal Hydrocortisone for Preventing or Treating Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review , 2010, Neonatology.
[17] B. Yoder,et al. Time-Related Changes in Steroid Use and Bronchopulmonary Dysplasia in Preterm Infants , 2009, Pediatrics.
[18] J. Ioannidis,et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.
[19] L. Doyle,et al. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. , 2009, The Cochrane database of systematic reviews.
[20] A. V. van Kaam,et al. Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled Trials , 2009, Pediatrics.
[21] A. V. van Kaam,et al. Effects of Higher Versus Lower Dexamethasone Doses on Pulmonary and Neurodevelopmental Sequelae in Preterm Infants at Risk for Chronic Lung Disease: A Meta-analysis , 2008, Pediatrics.
[22] B. Schmidt,et al. Evidence-Based Neonatal Drug Therapy for Prevention of Bronchopulmonary Dysplasia in Very-Low-Birth-Weight Infants , 2008, Neonatology.
[23] Ba,et al. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. , 2007, Archives of pediatrics & adolescent medicine.
[24] Jonathan A C Sterne,et al. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. , 2007, American journal of epidemiology.
[25] K. Hsu,et al. Effects of Neonatal Corticosteroid Treatment on Hippocampal Synaptic Function , 2007, Pediatric Research.
[26] K. Watterberg,et al. Growth and Neurodevelopmental Outcomes After Early Low-Dose Hydrocortisone Treatment in Extremely Low Birth Weight Infants , 2007, Pediatrics.
[27] D. Grobbee,et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. , 2007, The Journal of pediatrics.
[28] L. Doornen,et al. Differences in Behavioral Outcome and Motor Development at School Age After Neonatal Treatment for Chronic Lung Disease with Dexamethasone versus Hydrocortisone , 2006, Pediatric Research.
[29] M. Walsh,et al. Changes in the Use of Postnatal Steroids for Bronchopulmonary Dysplasia in 3 Large Neonatal Networks , 2006, Pediatrics.
[30] E. Bancalari,et al. Definitions and diagnostic criteria for bronchopulmonary dysplasia. , 2006, Seminars in perinatology.
[31] J. Coalson. Pathology of bronchopulmonary dysplasia. , 2006, Seminars in Perinatology.
[32] A. Lusky,et al. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants , 2006, Archives of Disease in Childhood - Fetal and Neonatal Edition.
[33] N. Marlow,et al. Neurodevelopmental and Respiratory Follow-up Results at 7 Years for Children From the United Kingdom and Ireland Enrolled in a Randomized Trial of Early and Late Postnatal Corticosteroid Treatment, Systemic and Inhaled (the Open Study of Early Corticosteroid Treatment) , 2006, Pediatrics.
[34] M. Walsh,et al. Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary Dysplasia , 2005, Pediatrics.
[35] F. Lazeyras,et al. Structural and Functional Brain Development After Hydrocortisone Treatment for Neonatal Chronic Lung Disease , 2005, Pediatrics.
[36] M. Walsh,et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. , 2005, The Journal of pediatrics.
[37] M. Hallman,et al. Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy , 2005, European Journal of Pediatrics.
[38] I. Hozo,et al. Estimating the mean and variance from the median, range, and the size of a sample , 2005, BMC medical research methodology.
[39] L. Doyle,et al. Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk for Chronic Lung Disease , 2005, Pediatrics.
[40] B. B. Mettelman,et al. Follow-up at 15 Years of Preterm Infants From a Controlled Trial of Moderately Early Dexamethasone for the Prevention of Chronic Lung Disease , 2005, Pediatrics.
[41] J. Muraskas,et al. A Prospective, Randomized, Double-Masked Trial Comparing Low Dose to Conventional Dose Dexamethasone in Neonatal Chronic Lung Disease , 2004 .
[42] C. McEvoy,et al. Randomized, double‐blinded trial of low‐dose dexamethasone: II. Functional residual capacity and pulmonary outcome in very low birth weight infants at risk for bronchopulmonary dysplasia , 2004, Pediatric pulmonology.
[43] R. Teele,et al. A randomized trial of two dexamethasone regimens to reduce side‐effects in infants treated for chronic lung disease of prematurity , 2004, Journal of paediatrics and child health.
[44] J. Harding,et al. High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone , 2004, Pediatric Radiology.
[45] A. Zaritsky,et al. Neonatologists are using much less dexamethasone , 2003, Archives of disease in childhood. Fetal and neonatal edition.
[46] F. Bel,et al. Short‐ and long‐term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? , 2003, Acta paediatrica.
[47] J. Kaempf,et al. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. , 2003, Pediatrics.
[48] R. Ehrenkranz,et al. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.
[49] R. Ehrenkranz,et al. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.
[50] R. Ehrenkranz,et al. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.
[51] D. Knoppert,et al. Randomized Controlled Trial Comparing Two Regimes of Dexamethasone in the Neonate with Chronic Lung Disease , 2002 .
[52] J. Penrice,et al. Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease , 2002, Archives of disease in childhood. Fetal and neonatal edition.
[53] C. McEvoy,et al. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. , 2002, Pediatrics.
[54] C. Patterson,et al. A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. , 2001, Pediatrics.
[55] T. Bunch,et al. Circulating neutrophil concentration and respiratory distress in premature infants. , 2000, The Journal of pediatrics.
[56] A. Coates,et al. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors , 2000, Developmental medicine and child neurology.
[57] A. Jobe. The New BPD: An Arrest of Lung Development , 1999, Pediatric Research.
[58] J. Tyson,et al. Dexamethasone Therapy Increases Infection in Very Low Birth Weight Infants , 1999, Pediatrics.
[59] G. Tortorolo,et al. Effect on Growth of Two Different Dexamethasone Courses for Preterm Infants at Risk of Chronic Lung Disease , 1999, Pharmacology.
[60] D. J. Goldstein,et al. Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Outcome of Study Participants at 1-Year Adjusted Age , 1999, Pediatrics.
[61] J. Muraskas,et al. Pulse Versus Tapered Dosing Dexamethasone for Evolving Bronchopulmonary Dysplasia (BPD) , 1999 .
[62] H. Hörnchen,et al. Early versus late dexamethasone treatment in preterm infants at risk for chronic lung disease: a randomized pilot study , 1999, European Journal of Pediatrics.
[63] F. Bloomfield,et al. Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial. , 1998, The Journal of pediatrics.
[64] A. Husain,et al. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. , 1998, Human pathology.
[65] T. Yeh,et al. Early dexamethasone therapy in preterm infants: a follow-up study. , 1998, Pediatrics.
[66] J. Tyson,et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. , 1998, The New England journal of medicine.
[67] T. Yeh,et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. , 1997, Pediatrics.
[68] D. Carlton,et al. Role of neutrophils in lung vascular injury and edema after premature birth in lambs. , 1997, Journal of applied physiology.
[69] L. Wright,et al. DEXAMETHASONE THERAPY IN INFANTS AT RISK FOR CHRONIC LUNG DISEASE(CLD): A MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED TRIAL • 1399 , 1996, Pediatric Research.
[70] F. Mimouni,et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. , 1995, The Journal of pediatrics.
[71] C. McEvoy,et al. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. , 1995, Pediatrics.
[72] U. Tuor,et al. Prevention of hypoxic-ischemic damage with dexamethasone is dependent on age and not influenced by fasting , 1995, Experimental Neurology.
[73] P. Groneck,et al. Levels of Complement Anaphylatoxin C5a in Pulmonary Effluent Fluid of Infants at Risk for Chronic Lung Disease and Effects of Dexamethasone Treatment , 1993, Pediatric Research.
[74] P. Groneck,et al. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. , 1993, The Journal of pediatrics.
[75] J. Cummings,et al. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. , 1989, The New England journal of medicine.
[76] M. Ryan,et al. Children of birth weight <1000 g: Changing outcome between ages 2 and 5 years , 1987 .
[77] R. Mellins,et al. Bronchopulmonary dysplasia. Unresolved neonatal acute lung injury. , 1985, The American review of respiratory disease.
[78] W. Northway,et al. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. , 1967, The New England journal of medicine.
[79] T. O'Shea,et al. Aerobic fitness and physical activity levels of children born prematurely following randomization to postnatal dexamethasone. , 2011, The Journal of pediatrics.
[80] P. Ballabh,et al. Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: a pilot study , 2009, Journal of Perinatology.
[81] Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. , 2002, Paediatrics & child health.
[82] Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Collaborative Dexamethasone Trial Group. , 1991, Pediatrics.
[83] E. Bancalari,et al. Bronchopulmonary dysplasia. , 2001, American journal of respiratory and critical care medicine.